- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02824068
Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (STIG-Pompe-Study) (STIG)
February 5, 2021 updated by: Prof. Dr. Benedikt Schoser, LMU Klinikum
Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months
Long-term outcome in late-onset Pompe disease treated beyond 36 months (ATBIG-Pompe-Study), a multicenter, multinational, longitudinal, non-interventional observational study in subjects, at least 8 years old, diagnosed with late-onset Pompe disease retrospectively and prospectively collects data to understand clinical progression in terms of muscle and respiratory function, and clinical symptomology treated with alglucosidase alfa more than 36 months in 100 subjects.
Study Overview
Detailed Description
The presentation and course of late-onset Pompe disease is much less foreseeable than the classic infantile form.
Some patients experience a rapid worsening in skeletal muscle function leading to loss of ambulation and respiratory failure, while others progress less rapidly.
So there is a more inconstant response to treatment in skeletal muscle and lung function in the long-term.
Therefore, an unmet clinical need is the collection and analysis of long-term data of rhGAA enzyme replacement therapy (ERT) in late-onset Pompe disease patient aged 8 years and older.
The principal goal of our investigator driven study is to gain conclusive insight in long-term outcome data beyond 36 months up to 10 years of ERT treatment.
In addition we will collect biological samples from all patients for a future biomarker study including gene modifier search by genome and RNA seq (not part of this proposal).
This study may provide clinicians and researchers with a better understanding of late-onset Pompe disease under long-term treatment, to the benefit of all patients affected with late-onset Pompe disease, as well as, individuals and families with related diseases.
Study Type
Observational
Enrollment (Actual)
112
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany, 80336
- Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany
-
-
-
-
Sicily
-
Messina, Sicily, Italy, 98125
- 5. Department of Clinical and Experimental Medicine, Reference Center for Rare Neuromuscular Disorders, University of Messina, Italy
-
-
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital Taipei
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Late-onset Pompe patients, aged over 8 years with at least 36 months of glucosiase alfa treatment
Description
Inclusion Criteria:
- Late-onset Pompe patients, aged over 8 years.
- The patient is willing and able to provide signed informed consent.
- The patient (and patient's legal guardian if patient is under 18 years of age) must have the ability to comply with the clinical protocol.
- Long-term Myozyme treatment beyond 36 months.
- Known GAA genotype.
- GAA activity (Dried blood spot testing, or other methods).
Exclusion Criteria:
- - The patient is concurrently participating in another clinical study using Myozyme or other treatment.
- The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study.
- The patient has clinically significant organic disease (with the exception of symptoms relating to Pompe disease), including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, precludes participation in the study or potentially decreases survival.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
change in muscle function
Time Frame: 12 months
|
To evaluate the degree of change in muscle function over time in patients with Pompe disease.
% change in the 6-minute walking test (normal 600m in six minutes) between 0, 6 and 12 months of the study
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
data collection on survival, death and reason of deaths
Time Frame: 12 months
|
data collection on survival, death and reason of deaths during the full study period
|
12 months
|
changes in forced vital capacity (FVC)
Time Frame: 12 months
|
To evaluate the degree of change in lung function over time in patients with Pompe disease by % change of FVC in sitting and supine body position between 0, 6, and 12 months of the study
|
12 months
|
changes in minimal inspiratory pressure (MIP)
Time Frame: 12 months
|
To evaluate the degree of change in lung function over time in patients with Pompe disease: % change in minimal inspiratory pressure between 0, 6 and 12months of the study
|
12 months
|
changes in maximal expiratory pressure (MEP)
Time Frame: 12 months
|
To evaluate the degree of change in lung function over time in patients with Pompe disease % change in maximal expiratory pressure between 0, 6 and 12months of the study
|
12 months
|
changes in loss of ambulation
Time Frame: 12 months
|
% of patients with loss of ambulation at 12 months of the study
|
12 months
|
changes in Medical Research Council (MRC) Scale for Muscle Strength
Time Frame: 12 months
|
% of patients with changes in 5-point MRC (scale data at 12 months of the study
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Benedikt Schoser, MD, Friedrich-Baur-Institute, Dep. of Neurology Klinikum der Universitaet Muenchen Munich, Germany
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2016
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
December 31, 2020
Study Registration Dates
First Submitted
June 20, 2016
First Submitted That Met QC Criteria
July 5, 2016
First Posted (Estimate)
July 6, 2016
Study Record Updates
Last Update Posted (Actual)
February 10, 2021
Last Update Submitted That Met QC Criteria
February 5, 2021
Last Verified
February 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn
- Carbohydrate Metabolism, Inborn Errors
- Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Lysosomal Storage Diseases, Nervous System
- Glycogen Storage Disease
- Glycogen Storage Disease Type II
Other Study ID Numbers
- Po001-STIG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Patients have the right to get their own data set after the end of the study
IPD Sharing Time Frame
open access via the publication given link below
IPD Sharing Access Criteria
open access
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- CSR
Study Data/Documents
-
Clinical Study Report
Information comments: Open access of the full study report can be downloaded under above webpage of the Journal of Neurology
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pompe Disease
-
University of Erlangen-Nürnberg Medical SchoolRecruitingPompe Disease (Late-onset) | Pompe Disease | Pompe's Disease Juvenile Onset | Pompe Disease Infantile-OnsetGermany
-
Centre for Analytical Biochemistry and Biomedical...University of GiessenRecruiting
-
GeneCradle IncRecruitingPompe Disease Infantile-OnsetChina
-
Seventh Medical Center of PLA General HospitalGeneCradle Therapeutics, IncRecruiting
-
Fundació Institut de Recerca de l'Hospital de la...Genzyme, a Sanofi CompanyUnknownPompe Disease | Late Onset Pompe DiseaseSpain
-
Astellas Gene TherapiesRecruitingPompe Disease (Late-onset)United States, Taiwan, France, Spain
-
Amicus TherapeuticsCompletedPompe Disease (Late-onset)United States, Australia, Korea, Republic of, Japan, Taiwan, Belgium, Slovenia, New Zealand, United Kingdom, France, Argentina, Canada, Spain, Bosnia and Herzegovina, Germany, Sweden, Hungary, Austria, Bulgaria, Denmark, Greece, I... and more
-
Duke UniversityCompleted
-
Amicus TherapeuticsTerminatedLate-onset Pompe DiseaseUnited States, Canada, Australia, Belgium
-
BioMarin PharmaceuticalTerminatedLate-onset Pompe DiseaseUnited States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
Clinical Trials on glucosidase alfa
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II (GSD-II) | Pompe Disease | Glycogenesis 2 Acid Maltase DeficiencyUnited States, Canada, Australia
-
Genzyme, a Sanofi CompanyApproved for marketingGlycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe Disease (Late-Onset)United States
-
Genzyme, a Sanofi CompanyCompletedGlycogen Storage Disease Type II | Acid Maltase Deficiency Disease | Glycogenosis 2 | Pompe DiseaseUnited States
-
Amicus TherapeuticsCompleted
-
ShireCompleted
-
Jonsson Comprehensive Cancer CenterAmgenCompletedLymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant ConditionUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Clinical Affairs, L.L.C.TerminatedNeoplasms | Cancer | AnemiaUnited States
-
Philogen S.p.A.RecruitingCarcinoma, Basal Cell | Carcinoma, Cutaneous Squamous CellGermany, Poland, Switzerland
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With InhibitorsTaiwan, United Kingdom, Thailand, Serbia, Croatia, Italy, Poland, Romania, Hungary, Malaysia, United States, Austria, Brazil, Greece, Japan, Puerto Rico, Russian Federation, South Africa, Turkey